Recently Viewed
Clear All₹17.00
₹-0.04
(-0.23%)
As on 19-Mar-2026 13:27IST
Today’s Range
52 Week Range
Liquidity
Market cap
₹73 Cr
Revenue (TTM)
₹45 Cr
Net Profit (TTM)
₹-17 Cr
ROE
0 %
ROCE
-25.6 %
P/E Ratio
--
P/B Ratio
--
Industry P/E
--
EV/EBITDA
-9.2
Div. Yield
0 %
Debt to Equity
-3
Book Value
₹-5.3
EPS
₹-3.9
Face value
10
Shares outstanding
43,180,000
CFO
₹-45.36 Cr
EBITDA
₹-45.38 Cr
Net Profit
₹-55.52 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bharat Immuno
| -15.3 | -9.1 | -9.7 | -19.6 | -9.9 | -19.9 | -0.4 |
|
BSE Healthcare
| -3.6 | -3.4 | -3.7 | 3.4 | 24.8 | 15.6 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Bharat Immuno
| -17.9 | -32.2 | -11.4 | -31.7 | 12.0 | 598.8 | -38.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Bharat Immuno
|
17.0 | 72.6 | 44.6 | -16.6 | -- | 0 | -- | -- |
| 163.8 | 2,627.7 | 2,796.8 | 118.8 | 8.1 | 2.3 | 22.1 | 0.4 | |
| 28.4 | 8.7 | 0.5 | 0.0 | 8.3 | -1.1 | -- | 2.2 | |
| 449.1 | 10,732.6 | 3,262.7 | 439.0 | 15.3 | 16 | 24.4 | 3.6 | |
| 53.6 | 190.1 | 133.8 | -0.3 | -0.7 | -0.6 | -- | 1.9 | |
| 162.8 | 7,497.6 | 2,803.3 | 361.8 | 15.5 | 14 | 20.8 | 2.7 | |
| 1,010.5 | 21,325.1 | 2,169.9 | 332.9 | 20.9 | 15.4 | 64.1 | 9.0 | |
| 4,220.0 | 9,706.6 | 878.4 | 240.1 | 33.8 | 73.3 | 40.4 | 25.3 | |
| 38.1 | 564.1 | 0.0 | 1.6 | -- | -0.5 | 350.6 | 21.0 | |
| 24.8 | 56.3 | 51.4 | 4.5 | 22.0 | 5.2 | 12.5 | 0.6 |
No Review & Analysis are available.
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, manufactures and markets a range of pharmaceuticals products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, ready to use therapeutic... food, low calorie sweetener tablets, etc. The company was founded in 1989 and is based in Bulandshahr, India. Read more
Incorporated
1989
Chairman
Sudhanshu Vrati
Managing Director
Dhananjay Kumar Tiwary
Group
PSU
Headquarters
Bulandshahar, Uttar Pradesh
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Bharat Immunologicals & Biologicals Corporation Ltd is ₹17.00 (BSE) as of 19-Mar-2026 13:27 IST. Bharat Immunologicals & Biologicals Corporation Ltd has given a return of -9.9% in the last 3 years.
Since, TTM earnings of Bharat Immunologicals & Biologicals Corporation Ltd is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
0.00
|
-4.16
|
|
2022
|
0.00
|
-18.98
|
|
2021
|
0.00
|
83.21
|
|
2020
|
0.00
|
1.23
|
|
2019
|
0.00
|
1.08
|
The 52-week high and low of Bharat Immunologicals & Biologicals Corporation Ltd are Rs 28.80 and Rs 15.80 as of 19-Mar-2026.
Bharat Immunologicals & Biologicals Corporation Ltd has a market capitalisation of ₹ 73 Cr as on 19-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Bharat Immunologicals & Biologicals Corporation Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.